Cargando…
Correction to “Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction”
Autores principales: | Inghardt, Tord, Antonsson, Thomas, Ericsson, Cecilia, Hovdal, Daniel, Johannesson, Petra, Johansson, Carina, Jurva, Ulrik, Kajanus, Johan, Kull, Bengt, Michaëlsson, Erik, Pettersen, Anna, Sjögren, Tove, Sörensen, Henrik, Westerlund, Kristina, Lindstedt, Eva-Lotte |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574857/ https://www.ncbi.nlm.nih.gov/pubmed/36190771 http://dx.doi.org/10.1021/acs.jmedchem.2c01533 |
Ejemplares similares
-
Discovery of
AZD4831, a Mechanism-Based Irreversible
Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure
with Preserved Ejection Fraction
por: Inghardt, Tord, et al.
Publicado: (2022) -
Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction
por: Nelander, Karin, et al.
Publicado: (2021) -
Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo‐controlled, phase I study in healthy volunteers
por: Gan, Li‐Ming, et al.
Publicado: (2019) -
Mitochondrial myopathy, dysmorphism, exercise-induced vomiting and tachycardia the mutation m.4831G > A()
por: Finsterer, Josef, et al.
Publicado: (2017) -
Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability
por: Ericsson, Hans, et al.
Publicado: (2019)